Palatin Technologies Inc
PTN
Company Profile
Business description
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.
Contact
4B Cedar Brook Drive
CranburyNJ08512
USAT: +1 609 495-2200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
30
Stocks News & Analysis
stocks
Ask the analyst: Are IDP Education's woes temporary?
The global education services provider has gone from stock market darling to one of the ASX's weakest performers. What gives?
stocks
Is it time to buy the Magnificent Seven?
After the recent selloff, the bull market’s most in-demand stocks look much cheaper.
stocks
Chart of the week: Did ASX companies underwhelm or impress during earnings season?
The Chart of the Week looks at how our Fair Values changes for Australian companies during earnings season.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,966.60 | 36.00 | -0.45% |
| CAC 40 | 7,938.21 | 50.75 | -0.64% |
| DAX 40 | 22,567.14 | 109.27 | -0.48% |
| Dow JONES (US) | 40,661.77 | 689.16 | -1.67% |
| FTSE 100 | 8,542.56 | 1.59 | 0.02% |
| HKSE | 23,462.65 | 137.66 | -0.58% |
| NASDAQ | 17,244.74 | 403.71 | -2.29% |
| Nikkei 225 | 36,790.03 | 29.06 | -0.08% |
| NZX 50 Index | 12,209.05 | 40.50 | -0.33% |
| S&P 500 | 5,504.88 | 94.42 | -1.69% |
| S&P/ASX 200 | 7,749.10 | 37.10 | -0.48% |
| SSE Composite Index | 3,358.73 | 13.20 | -0.39% |